An amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration and its preparation method
By preparing an amino acid hydrogel and amorphous calcium phosphate composite material, the problems of insufficient bioactivity and mechanical strength of existing bone defect repair materials have been solved, achieving stable delivery and rapid osteogenic bone tissue regeneration, with good biocompatibility and promising industrial application prospects.
Patent Information
- Application Number
- CN202311614764.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-29
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-11-29
AI Technical Summary
Existing bone defect repair materials are inadequate in terms of bioactivity, mechanical strength, and integration speed with the body, making it difficult to effectively guide the regeneration of bone tissue micro and macro structures. Furthermore, existing hydrogel materials are prone to deformation in vivo, have poor mechanical properties, and high concentrations of polyanions may have biotoxic effects on cells.
By preparing an amino acid hydrogel/amorphous calcium phosphate composite material, an amino acid hydrogel/amorphous calcium phosphate composite material with excellent mechanical properties and biocompatibility was prepared by mixing acryloyl amino acid monomers with soluble calcium salt and phosphate solutions, adding crosslinking agents and photoinitiators, and carrying out free radical polymerization.
It achieves stable delivery of amorphous calcium phosphate in bone defect areas, promotes bone tissue regeneration, has excellent mechanical properties and biocompatibility, significantly improves osteogenic rate, and is suitable for industrial production.
Smart Images

Figure CN117599253B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical materials technology, and in particular to an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration and its preparation method. Background Technology
[0002] Bone tissue not only provides structure and support for the body but also plays a crucial role in various physiological processes, including movement and the protection of internal organs. However, various causes such as trauma, fractures, infections, and tumor resection can lead to bone defects, resulting in functional impairment, pain, deformities, and other problems, severely impacting patients' quality of life and social adaptation. Therefore, there is a significant clinical need to promote bone regeneration in defect areas.
[0003] Currently, autologous bone grafting remains the "gold standard" for bone defect repair due to its advantages such as the absence of rejection. Commonly used bone grafts in clinical practice include the iliac crest, ribs, and fibula, especially vascularized bone segments anastomosed with blood vessels around the defect area, providing ample nutrition for bone growth and healing. However, the availability and remodeling capabilities of autologous bone are limited, making it difficult to apply to the repair of large-scale tissue defects. The incision of a second surgical site also increases the risk of infection and other complications, restricting its clinical application. Emerging bioactive materials, with their controllable mechanical strength, can act as scaffolds and can be combined with growth factors or therapeutic drugs. They can promote cell adhesion and proliferation, induce extracellular matrix secretion, and promote new bone formation, making them a promising treatment for bone defect regeneration.
[0004] Clinically, a wide variety of synthetic bone graft materials are used, including calcium phosphate ceramics, bioglass, metals, and polymers. However, these synthetic bone graft materials still suffer from problems such as poor bioactivity, low vascularization, slow integration with the body, and insufficient osteogenic properties, making it difficult to achieve satisfactory clinical results. Ultimately, this is because these materials have poor biomimicry; they only mimic the components of mature bone tissue, the end product of bone formation, and cannot guide the reconstruction of the micro and macroscopic structures of bone tissue at the defect site.
[0005] The core scientific question behind overcoming this bottleneck is how to guide the regeneration of bone tissue's micro and macro structures in a "bottom-up" manner using bone graft materials. Early-stage bone formation does not occur through the classic nucleation process of calcium phosphate crystals, but rather relies on the participation of amorphous calcium phosphate (ACP), a mineralization precursor. ACP first deposits in specific regions of the bone collagen matrix, subsequently undergoing crystallization to form mineralized collagen fibers. This process forms the structural basis of bone tissue and is a key "source" of "bottom-up" bone formation. However, the amorphous nature of ACP makes it prone to crystalline transformation during storage and application. The bone matrix contains approximately 10-15% non-collagenous proteins, which are rich in glutamate and aspartic acid. The latter contains a large number of carboxyl groups, which can stabilize ACP in a concentration-dependent manner by chelating calcium ions. Researchers such as Tang Ruikang (Osteoporotic Bone Recovery by a Highly Bone-Inductive Calcium Phosphate Polymer-Induced Liquid-Precursor. Adv. Sci. 2019, 6(19): 1900683; Intraosseous Injection of Calcium Phosphate Polymer-Induced Liquid Precursor Increases Bone Density and Improves Early Implant Osseointegration in Ovariectomized Rats. Int. J. Nanomedicine. 2021, 16: 6217-6229.) used negatively charged polyanionic hydrogels, such as polyacrylic acid (PAA) and polyaspartic acid (PASP), to load ACP nanoclusters for the treatment of diseases such as bone defects or osteoporosis. Animal experiments have shown that, compared with collagen-based biomimetic bone matrix and polyanionic hydrogel loaded with HA used in clinical practice, polyanionic hydrogel loaded with ACP exhibits superior osteogenic properties. However, this type of hydrogel has poor mechanical properties and is prone to deformation after implantation, failing to provide the early mechanical support required for bone defect repair. Furthermore, other researchers (Bioinspired Silk Fibroin Mineralization for Advanced In Vitro Bone Remodeling Models. Adv. Funct. Mater. 2022, 32, 2206992.) have explored another application method: using silk fibroin as a scaffold and adding polyanionic (PASP) to stabilize amorphous calcium phosphate. However, high concentrations of polyanionic phosphate can have potential biotoxicity to bone tissue cells.Currently, there is a lack of scaffold materials with good biocompatibility and stable delivery of ACP. Summary of the Invention
[0006] To overcome the shortcomings of existing technologies, the present invention aims to provide an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration and its preparation method. The method involves preparing amino acid hydrogel monomers with different quantities and carboxyl group structures, adding amorphous calcium phosphate to the amino acid hydrogel monomers, and then performing free radical polymerization to prepare an amino acid hydrogel loaded with amorphous calcium phosphate. This hydrogel exhibits excellent mechanical properties and a good ability to stabilize amorphous calcium phosphate, which is beneficial for the application of the amino acid hydrogel / amorphous calcium phosphate composite material in the repair and regeneration of bone defects.
[0007] To achieve the above-mentioned objectives, the technical solution adopted by this invention is as follows:
[0008] A method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration includes the following steps:
[0009] Step 1: Dissolve acryloyl amino acid monomer powder in double-distilled water to obtain a 1-3 mol / L acryloyl amino acid monomer solution;
[0010] Step 2: Mix the acryloyl amino acid monomer solution obtained in Step 1 with the soluble calcium salt solution and stir for 2-30 minutes. Then, add the phosphate solution dropwise and continue stirring for 2-30 minutes to obtain mixed solution A.
[0011] Step 3: Mix and stir the mixed solution A obtained in Step 2 with the crosslinking agent to obtain mixed solution B;
[0012] Step 4: Mix the mixed solution B obtained in Step 3 with the photoinitiator and stir for 2-30 minutes. Then, under blue light or ultraviolet light irradiation, initiate the polymerization reaction to obtain an amino acid hydrogel / amorphous calcium phosphate composite material.
[0013] The preparation process of the acryloyl amino acid monomer powder in step 1 is as follows:
[0014] Step 1.1: Mix amino acids with acryloyl chloride and react them. During the reaction, adjust the pH of the reaction solution to 7.5-8.5. After the reaction is complete, adjust the pH of the reaction solution to 10.5-11.5 to obtain an alkaline solution. The molar ratio of the amino acids to acryloyl chloride is 1:(1.0-1.5). The amino acids are glycine, aspartic acid, and glutamic acid.
[0015] Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate to obtain a washed alkaline solution; adjust the pH of the washed alkaline solution to 1.5-2.5 to obtain an acidic solution; the volume ratio of ethyl acetate to alkaline solution is 1:(2-4);
[0016] Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, and then rotary evaporate to obtain a concentrated solution; the volume ratio of ethyl acetate to acidic solution is 1:(2-4);
[0017] Step 1.4: The concentrate obtained in Step 1.3 is settled, centrifuged, and dried using n-hexane to obtain acryloyl amino acid monomer powder; the volume ratio of n-hexane to concentrate is 1:(5-8); the acryloyl amino acid monomer includes acryloylglycine, acryloylaspartic acid, or acryloylglutamic acid.
[0018] The amino acids in step 1.1 may also be alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, glutamine, threonine, aspartic acid, lysine, arginine, or histidine.
[0019] The room temperature reaction time in step 1.1 is 3-4 hours; the rotary evaporation temperature in step 1.3 is 20℃-30℃; the centrifugation speed in step 1.4 is 3000-10000 rpm, the centrifugation time is 2-5 minutes, the drying time is 3-8 hours, and the pressure is 0 to -0.1 MPa.
[0020] In step 2, the volume ratio of the acryloyl amino acid monomer solution, the soluble calcium salt solution, and the phosphate solution is (20-50):(5-15):(2-9); the concentration of the soluble calcium salt solution is 10-30 mmol / L, and the concentration of the phosphate solution is 4-18 mmol / L.
[0021] In step 2, the soluble calcium salt solution is CaCl2, CaCl2·2H2O, Ca(NO3)2, or Ca(NO3)2·4H2O; the phosphate solution is Na2HPO4, K2HPO4, or (NH4)2HPO4.
[0022] In step 3, the volume ratio of mixed solution A to crosslinking agent is (100-400):1; the stirring time is 2-30 min; the crosslinking agent is polyethylene glycol diacrylate (PEGDA), the average molecular weight of PEGDA is 250-10000, and the mass concentration of the crosslinking agent is 0.05%-0.2%.
[0023] In step 4, the volume ratio of mixed solution B to photoinitiator is (15-40):1; the photoinitiator is 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone (2959), 2-hydroxy-2-methyl-1-phenyl-1-propanone (1173) or lithium phenyl (2,4,6-trimethylbenzoyl)phosphate (LAP), the mass concentration of the photoinitiator is 2%-6%, and the crosslinking reaction time is 5-30s.
[0024] The present invention also discloses an amino acid hydrogel / amorphous calcium phosphate composite material, which is prepared by a method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration.
[0025] The amino acid hydrogel / amorphous calcium phosphate composite material is an acryloylglycine / amorphous calcium phosphate composite material, an acryloylaspartic acid / amorphous calcium phosphate composite material, or an acryloylglutamic acid / amorphous calcium phosphate composite material.
[0026] Compared with the prior art, the present invention has the following advantages:
[0027] 1. The storage modulus of the amino acid hydrogel / amorphous calcium phosphate composite material prepared by this invention is greater than the loss modulus, indicating that the bulk phase of the composite material is more like an elastic solid. The frequency oscillation test did not destroy the bulk phase structure. At the same time, the compressive strength of the amino acid hydrogel / amorphous calcium phosphate composite material is at least 400 kPa at 85% strain, which shows excellent mechanical properties. Moreover, the crystallinity of calcium phosphate in the amino acid hydrogel / amorphous calcium phosphate composite material is less than 80%, indicating that the composite material can stably deliver amorphous calcium phosphate to the bone defect area as a bone repair material, thereby realizing bone tissue regeneration.
[0028] 2. Compared with the high concentration of polyanions in the prior art, the amino acid hydrogel monomer prepared by this invention has low cytotoxicity, excellent biocompatibility, and is beneficial to bone formation in vivo.
[0029] 3. Compared with the osteogenic rate of BNP@CS-GEL (where CS-GEL is chondroitin sulfate methacrylate and gelatin, and BNP is baicalin) prepared in the existing literature, the new bone formation rate after treatment with the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention can reach 3-4 μm per day, which significantly improves the osteogenic rate.
[0030] 4. This invention prepares an amino acid hydrogel loaded with amorphous calcium phosphate by free radical polymerization of amino acid hydrogel monomers with different amounts and carboxyl group structures. The preparation method is simple, the raw materials are readily available, the cost is low, and it is suitable for industrial-scale production.
[0031] In summary, the amino acid hydrogel / amorphous calcium phosphate composite material prepared by this invention possesses excellent mechanical properties and the ability to stably deliver amorphous calcium phosphate. It can serve as a scaffold material in bone defect areas and promote in vivo bone formation through the synthesized amorphous calcium phosphate (ACP). Furthermore, it exhibits excellent biocompatibility, meeting the performance requirements for materials used in clinical bone defect regeneration and repair. It shows great promise for repairing irregular bone defects and promoting bone defect regeneration. Attached Figure Description
[0032] Figure 1 The curves show the changes in storage modulus and loss modulus of the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention as a function of oscillation frequency.
[0033] Figure 2 This is a curve showing the change in crystallinity over time of the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention.
[0034] Figure 3 This is a fluorescence microscope image of MC3T3-E1 cells treated with the acryloylglycine hydrogel / amorphous calcium phosphate composite material prepared in this invention.
[0035] Figure 4 This is a fluorescence microscope image of MC3T3-E1 cells treated with the acryloyl aspartic acid hydrogel / amorphous calcium phosphate composite material prepared in this invention.
[0036] Figure 5 This is a fluorescence microscope image of MC3T3-E1 cells treated with the acryloylglutamic acid hydrogel / amorphous calcium phosphate composite material prepared in this invention.
[0037] Figure 6 This refers to the expression levels of osteogenic-related genes in MC3T3-E1 cells treated with the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention.
[0038] Figure 7 This invention describes the rate of new bone formation in rats with skull defects treated with the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention.
[0039] Figure 8 This represents the rate of new bone formation in rats with skull defects treated with BNP@CS-GEL material prepared in existing literature. Detailed Implementation
[0040] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments and accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments.
[0041] A method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration includes the following steps:
[0042] Step 1: Preparation of Acryloyl amino acid monomer powder
[0043] Step 1.1: Mix amino acids with acryloyl chloride and react them, wherein the molar ratio of amino acids to acryloyl chloride is 1:(1-1.5), preferably 1:1.1; react at room temperature for 3-4 hours, preferably 3.75 hours; adjust the pH of the solution to 7.5-8.5 during the reaction, preferably 8; then after the reaction is completed, adjust the pH of the reaction solution to 10.5-11.5, preferably 11, to obtain an alkaline solution; wherein the amino acids are glycine, aspartic acid, glutamic acid, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, glutamine, threonine, aspartic acid, lysine, arginine, or histidine;
[0044] Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate. The volume ratio of ethyl acetate to alkaline solution is 1:(2-4), preferably 1:3, to obtain a washed alkaline solution. Ethyl acetate can remove unreacted acryloyl chloride in the alkaline solution. Adjust the pH of the washed alkaline solution to 1.5-2.5, preferably 2, to obtain an acidic solution.
[0045] Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, wherein the volume ratio of ethyl acetate to acidic solution is 1:(2-4), preferably 1:3; evaporate the extracted acidic solution using a rotary evaporator at a temperature of 20℃-30℃, preferably 25℃, to obtain a concentrated solution;
[0046] Step 1.4: The concentrate obtained in Step 1.3 is settled using n-hexane, with a volume ratio of n-hexane to concentrate of 1:(5-8), preferably 1:6; the settled concentrate is vortexed using a vortex mixer to mix evenly, and then centrifuged to obtain a precipitate; the centrifugation speed is 3000-10000 rpm, preferably 5000 rpm, and the centrifugation time is 2-5 min, preferably 3.5 min; the precipitate is dried in a vacuum drying oven for 3-8 h, preferably 4 h, at a pressure of 0 to -0.1 MPa, preferably -0.1 MPa, to obtain acryloyl amino acid monomer powder; the vacuum drying oven is a Tester / DZ53T model; the acryloyl amino acid monomer includes acryloylglycine, acryloylaspartic acid, or acryloylglutamic acid;
[0047] Step 2: Dissolve the acryloyl amino acid monomer powder from Step 1 in double-distilled water, and vortex the mixture to obtain a homogeneous solution of acryloyl amino acid monomer with a concentration of 1-3 mol / L.
[0048] Step 3: Place the acryloyl amino acid monomer solution obtained in Step 2 and a 10-30 mmol / L soluble calcium salt solution on a magnetic stirrer and stir for 2-30 min, preferably 10 min; then add a 4-18 mmol / L phosphate solution dropwise and stir on a magnetic stirrer for 2-30 min, preferably 10 min. The volume ratio of the acryloyl amino acid monomer solution, the soluble calcium salt solution, and the phosphate solution is (20-50):(5-15):(2-9), preferably 20:5:3, to obtain mixed solution A; the soluble calcium salt solution is CaCl2, CaCl2·2H2O, Ca(NO3)2, or Ca(NO3)2·4H2O; the phosphate solution is Na2HPO4, K2HPO4, or (NH4)2HPO4.
[0049] Step 4: Place the mixed solution A obtained in Step 3 and the crosslinking agent on a magnetic stirrer and mix them. The volume ratio of the mixed solution A to the crosslinking agent is (100-400):1, preferably 200:1. The stirring time is 2-30 min, preferably 10 min, to obtain mixed solution B. The crosslinking agent is polyethylene glycol diacrylate (PEGDA), the average molecular weight of PEGDA is 250-10000, preferably 1000, and the mass concentration of the crosslinking agent is 0.05%-0.2%, preferably 0.1%.
[0050] Step 5: Add a photoinitiator to the mixed solution B obtained in Step 4 and mix and stir for 2-30 min. Then, initiate the polymerization reaction under blue light or ultraviolet light irradiation. The mass concentration of the photoinitiator is 2%-6%, preferably 5%. The volume ratio of the mixed solution B to the photoinitiator is (15-40):1, preferably 20:1. The photoinitiator is 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone (2959), 2-hydroxy-2-methyl-1-phenyl-1-propanone (1173), or lithium phenyl (2,4,6-trimethylbenzoyl)phosphate (LAP). The crosslinking reaction time is 5-30 s, preferably 10 s, to obtain an amino acid hydrogel / amorphous calcium phosphate composite material. The amino acid hydrogel / amorphous calcium phosphate composite material is acryloylglycine / amorphous calcium phosphate composite material, acryloylaspartic acid / amorphous calcium phosphate composite material, or acryloylglutamic acid / amorphous calcium phosphate composite material.
[0051] Example 1
[0052] A method for preparing an acryloylglycine / amorphous calcium phosphate composite material for bone defect regeneration includes the following steps:
[0053] Step 1: Preparation of Acryloylglycine monomer powder
[0054] Step 1.1: Glycine and acryloyl chloride are mixed and reacted in a molar ratio of 1:1. The reaction is carried out at room temperature for 3 hours. The pH of the solution is adjusted to 7.5 during the reaction process. After the reaction is completed, the pH of the reaction solution is adjusted to 10.5 to obtain an alkaline solution.
[0055] Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate, with a volume ratio of ethyl acetate to alkaline solution of 1:2, to obtain a washed alkaline solution; adjust the pH value of the washed alkaline solution to 1.5 to obtain an acidic solution;
[0056] Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, the volume ratio of ethyl acetate to acidic solution being 1:2; evaporate the extracted acidic solution using a rotary evaporator at a temperature of 20°C to obtain a concentrated solution;
[0057] Step 1.4: The concentrate obtained in Step 1.3 is settled using n-hexane, with a volume ratio of n-hexane to concentrate of 1:5; the settled concentrate is vortexed and mixed evenly using a vortex mixer, and then centrifuged to obtain a precipitate; the centrifugation speed is 3000 rpm and the centrifugation time is 2 min; the precipitate is dried in a vacuum drying oven for 3 h at a pressure of -0.05 MPa to obtain acryloylglycine monomer powder;
[0058] Step 2: Dissolve the acryloylglycine monomer powder from Step 1 in double-distilled water, and vortex the mixture to obtain a homogeneous acryloylglycine monomer solution with a concentration of 1 mol / L.
[0059] Step 3: Place the acryloylglycine monomer solution obtained in Step 2 and 10 mmol / L CaCl2 solution on a magnetic stirrer and stir for 2 min; then add 4 mmol / L Na2HPO4 solution dropwise and stir on a magnetic stirrer for 2 min. The volume ratio of the acryloylglycine monomer solution, CaCl2 solution and Na2HPO4 solution is 50:5:2 to obtain mixed solution A.
[0060] Step 4: Mix the mixed solution A obtained in Step 3 with polyethylene glycol diacrylate (PEGDA) on a magnetic stirrer; the volume ratio of mixed solution A to polyethylene glycol diacrylate (PEGDA) is 400:1, and the stirring time is 2 minutes to obtain mixed solution B; the average molecular weight of polyethylene glycol diacrylate (PEGDA) is 250, and the mass concentration of polyethylene glycol diacrylate (PEGDA) is 0.05%;
[0061] Step 5: Add photoinitiator LAP to the mixed solution B obtained in Step 4 and mix and stir for 2 min. Then, initiate the polymerization reaction under blue light irradiation. The mass concentration of photoinitiator LAP is 2%, the volume ratio of mixed solution B to photoinitiator LAP is 40:1, and the crosslinking reaction time is 5 s. Acryloylglycine / amorphous calcium phosphate composite material is obtained and named PACG-ACP.
[0062] Example 2
[0063] A method for preparing an acryloyl aspartic acid / amorphous calcium phosphate composite material for bone defect regeneration includes the following steps:
[0064] Step 1: Preparation of Acryloylaspartic acid monomer powder
[0065] Step 1.1: Mix aspartic acid and acryloyl chloride and react them. The molar ratio of aspartic acid to acryloyl chloride is 1:1.1. React at room temperature for 3.75 h. Adjust the pH of the solution to 8 during the reaction process. After the reaction is completed, adjust the pH of the reaction solution to 11 to obtain an alkaline solution.
[0066] Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate, with a volume ratio of ethyl acetate to alkaline solution of 1:3, to obtain a washed alkaline solution; adjust the pH value of the washed alkaline solution to 2 to obtain an acidic solution;
[0067] Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, the volume ratio of ethyl acetate to acidic solution being 1:3; evaporate the extracted acidic solution using a rotary evaporator at a temperature of 25°C to obtain a concentrated solution;
[0068] Step 1.4: The concentrate obtained in Step 1.3 is settled using n-hexane, with a volume ratio of n-hexane to concentrate of 1:6; the settled concentrate is vortexed and mixed evenly using a vortex mixer, and then centrifuged to obtain a precipitate; the centrifugation speed is 5000 rpm and the centrifugation time is 3.5 min; the precipitate is dried in a vacuum drying oven for 4 h at a pressure of -0.1 MPa to obtain acryloyl aspartic acid monomer powder;
[0069] Step 2: Dissolve the acryloyl aspartic acid monomer powder from Step 1 in double-distilled water, and vortex the mixture to obtain a acryloyl aspartic acid monomer solution with a concentration of 2.5 mol / L.
[0070] Step 3: Place the acryloyl aspartic acid monomer solution obtained in Step 2 and 20 mmol / L CaCl2 solution on a magnetic stirrer and stir for 10 min; then add 12 mmol / L Na2HPO4 solution dropwise and stir on a magnetic stirrer for 10 min. The volume ratio of the acryloyl aspartic acid monomer solution, CaCl2 solution and Na2HPO4 solution is 20:5:3 to obtain mixed solution A.
[0071] Step 4: Mix the mixed solution A obtained in Step 3 with polyethylene glycol diacrylate (PEGDA) on a magnetic stirrer; the volume ratio of mixed solution A to polyethylene glycol diacrylate (PEGDA) is 200:1, and the stirring time is 10 min to obtain mixed solution B; the average molecular weight of polyethylene glycol diacrylate (PEGDA) is 1000, and the mass concentration of polyethylene glycol diacrylate (PEGDA) is 0.1%;
[0072] Step 5: Add photoinitiator LAP to the mixed solution B obtained in Step 4 and mix and stir for 10 min. Then, initiate the polymerization reaction under blue light irradiation. The mass concentration of photoinitiator LAP is 5%, the volume ratio of mixed solution B to photoinitiator LAP is 20:1, and the crosslinking reaction time is 10 s. Acryloyl aspartic acid / amorphous calcium phosphate composite material is obtained and named PAASP-ACP.
[0073] Example 3
[0074] A method for preparing an acryloylglutamic acid / amorphous calcium phosphate composite material for bone defect regeneration includes the following steps:
[0075] Step 1: Preparation of Acryloylglutamic acid monomer powder
[0076] Step 1.1: Mix glutamic acid and acryloyl chloride and react them. The molar ratio of glutamic acid to acryloyl chloride is 1:1.5. React at room temperature for 4 hours. Adjust the pH of the solution to 8.5 during the reaction process. After the reaction is completed, adjust the pH of the reaction solution to 11.5 to obtain an alkaline solution.
[0077] Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate, the volume ratio of ethyl acetate to alkaline solution being 1:4, to obtain a washed alkaline solution; adjust the pH value of the washed alkaline solution to 2.5 to obtain an acidic solution;
[0078] Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, the volume ratio of ethyl acetate to acidic solution being 1:4; evaporate the extracted acidic solution using a rotary evaporator at a temperature of 30°C to obtain a concentrated solution;
[0079] Step 1.4: The concentrate obtained in Step 1.3 is settled using n-hexane, with a volume ratio of n-hexane to concentrate of 1:8; the settled concentrate is vortexed and mixed evenly using a vortex mixer, and then centrifuged to obtain a precipitate; the centrifugation speed is 10000 rpm and the centrifugation time is 5 min; the precipitate is dried in a vacuum drying oven for 8 h at a pressure of -0.1 MPa to obtain acryloylglutamic acid monomer powder;
[0080] Step 2: Dissolve the acryloylglutamic acid monomer powder from Step 1 in double-distilled water, and vortex the mixture to obtain a homogeneous solution of acryloylglutamic acid monomer with a concentration of 3 mol / L.
[0081] Step 3: The acryloyl aspartic acid monomer solution obtained in Step 2 and 25 mmol / L CaCl2·2H2O solution were placed on a magnetic stirrer and stirred for 15 min; then 15 mmol / L K2HPO4 solution was added dropwise and stirred on a magnetic stirrer for 15 min. The volume ratio of the acryloyl glutamic acid monomer solution, CaCl2·2H2O solution and K2HPO4 solution was 50:15:9, resulting in mixed solution A.
[0082] Step 4: Mix the mixed solution A obtained in Step 3 with polyethylene glycol diacrylate (PEGDA) on a magnetic stirrer; the volume ratio of mixed solution A to polyethylene glycol diacrylate (PEGDA) is 100:1, and the stirring time is 30 min to obtain mixed solution B; the average molecular weight of polyethylene glycol diacrylate (PEGDA) is 10000, and the concentration of polyethylene glycol diacrylate (PEGDA) is 0.2% by mass;
[0083] Step 5: Add photoinitiator 2959 to the mixed solution B obtained in Step 4 and mix and stir for 15 min. Then, initiate the polymerization reaction under blue light irradiation. The mass concentration of photoinitiator LAP is 6%, the volume ratio of the mixed solution B to photoinitiator 2959 is 15:1, and the crosslinking reaction time is 30 s. Acryloylglutamic acid / amorphous calcium phosphate composite material is obtained and named PAGLU-ACP.
[0084] Example 4
[0085] A method for preparing an acryloyl aspartic acid / amorphous calcium phosphate composite material for bone defect regeneration includes the following steps:
[0086] Step 1: Preparation of Acryloylaspartic acid monomer powder
[0087] Step 1.1: Mix aspartic acid and acryloyl chloride and react them. The molar ratio of aspartic acid to acryloyl chloride is 1:1.3. React at room temperature for 3.5 hours. Adjust the pH of the solution to 8.2 during the reaction process. After the reaction is completed, adjust the pH of the reaction solution to 11.3 to obtain an alkaline solution.
[0088] Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate, the volume ratio of ethyl acetate to alkaline solution being 1:3.5, to obtain a washed alkaline solution; adjust the pH value of the washed alkaline solution to 2.3 to obtain an acidic solution;
[0089] Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, the volume ratio of ethyl acetate to acidic solution being 1:3.5; then, evaporate the extracted acidic solution using a rotary evaporator at a temperature of 28°C to obtain a concentrated solution.
[0090] Step 1.4: The concentrate obtained in Step 1.3 is settled using n-hexane, with a volume ratio of n-hexane to concentrate of 1:7; the settled concentrate is vortexed and mixed evenly using a vortex mixer, and then centrifuged to obtain a precipitate; the centrifugation speed is 8000 rpm and the centrifugation time is 4 min; the precipitate is dried in a vacuum drying oven for 6 h at a pressure of -0.1 MPa to obtain acryloyl aspartic acid monomer powder;
[0091] Step 2: Dissolve the acryloyl aspartic acid monomer powder from Step 1 in double-distilled water, and vortex the mixture to obtain a acryloyl aspartic acid monomer solution with a concentration of 2.8 mol / L.
[0092] Step 3: The acryloyl aspartic acid monomer solution obtained in Step 2 and 30 mmol / L Ca(NO3)2 solution are placed on a magnetic stirrer and stirred for 15 min; then 18 mmol / L K2HPO4 solution is added dropwise and stirred on a magnetic stirrer for 15 min. The volume ratio of the acryloyl aspartic acid monomer solution, Ca(NO3)2 solution and K2HPO4 solution is 50:15:9, to obtain mixed solution A.
[0093] Step 4: Mix the mixed solution A obtained in Step 3 with polyethylene glycol diacrylate (PEGDA) on a magnetic stirrer; the volume ratio of mixed solution A to polyethylene glycol diacrylate (PEGDA) is 300:1, and the stirring time is 15 min to obtain mixed solution B; the average molecular weight of polyethylene glycol diacrylate (PEGDA) is 1000, and the mass concentration of polyethylene glycol diacrylate (PEGDA) is 0.15%;
[0094] Step 5: Add photoinitiator 1173 to the mixed solution B obtained in step 4 and mix and stir for 15 min. Then, initiate the polymerization reaction under ultraviolet light irradiation. The mass concentration of photoinitiator LAP is 5%, the volume ratio of the mixed solution B to photoinitiator 1173 is 30:1, and the crosslinking reaction time is 20 s to obtain acryloyl aspartic acid / amorphous calcium phosphate composite material.
[0095] Example 5
[0096] A method for preparing an acryloyl aspartic acid / amorphous calcium phosphate composite material for bone defect regeneration includes the following steps:
[0097] Step 1: Preparation of Acryloylaspartic acid monomer powder
[0098] Step 1.1: Mix aspartic acid and acryloyl chloride and react them. The molar ratio of aspartic acid to acryloyl chloride is 1:1. React at room temperature for 3.5 hours. Adjust the pH of the solution to 7.8 during the reaction. After the reaction is completed, adjust the pH of the reaction solution to 10.8 to obtain an alkaline solution.
[0099] Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate, the volume ratio of ethyl acetate to alkaline solution being 1:2.5, to obtain a washed alkaline solution; adjust the pH value of the washed alkaline solution to 1.8 to obtain an acidic solution;
[0100] Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, the volume ratio of ethyl acetate to acidic solution being 1:2.5; evaporate the extracted acidic solution using a rotary evaporator at a temperature of 22°C to obtain a concentrated solution;
[0101] Step 1.4: The concentrate obtained in Step 1.3 is settled using n-hexane, with a volume ratio of n-hexane to concentrate of 1:5; the settled concentrate is vortexed and mixed evenly using a vortex mixer, and then centrifuged to obtain a precipitate; the centrifugation speed is 4000 rpm and the centrifugation time is 3 min; the precipitate is dried in a vacuum drying oven for 3 h at a pressure of -0.1 MPa to obtain acryloyl aspartic acid monomer powder;
[0102] Step 2: Dissolve the acryloyl aspartic acid monomer powder from Step 1 in double-distilled water, and vortex the mixture to obtain a acryloyl aspartic acid monomer solution with a concentration of 2 mol / L.
[0103] Step 3: The acryloyl aspartic acid monomer solution obtained in Step 2 and 20 mmol / L Ca(NO3)2·4H2O solution are placed on a magnetic stirrer and stirred for 5 min; then 12 mmol / L (NH4)2HPO4 solution is added dropwise and stirred on a magnetic stirrer for 5 min. The volume ratio of the acryloyl aspartic acid monomer solution, Ca(NO3)2·4H2O solution and (NH4)2HPO4 solution is 25:5:3, to obtain mixed solution A.
[0104] Step 4: Mix the mixed solution A obtained in Step 3 with polyethylene glycol diacrylate (PEGDA) on a magnetic stirrer; the volume ratio of mixed solution A to polyethylene glycol diacrylate (PEGDA) is 150:1, and the stirring time is 5 min to obtain mixed solution B; the average molecular weight of polyethylene glycol diacrylate (PEGDA) is 1000, and the mass concentration of polyethylene glycol diacrylate (PEGDA) is 0.08%;
[0105] Step 5: Add photoinitiator LAP to the mixed solution B obtained in Step 4 and mix and stir for 5 minutes. Then, initiate the polymerization reaction under ultraviolet light irradiation. The mass concentration of photoinitiator LAP is 3%, the volume ratio of mixed solution B to photoinitiator LAP is 18:1, and the crosslinking reaction time is 8 seconds to obtain acryloyl aspartic acid / amorphous calcium phosphate composite material.
[0106] Figure 1The storage modulus and loss modulus of acryloylglycine hydrogel / amorphous calcium phosphate (PACG-ACP), acryloylaspartic acid hydrogel / amorphous calcium phosphate (PAASP-ACP), and acryloylglutamic acid hydrogel / amorphous calcium phosphate (PAGLU-ACP) are curves showing the variation of energy with oscillation frequency. Figure 1 It can be seen that the storage modulus G' of each group of amino acid hydrogel / amorphous calcium phosphate composites is greater than the loss modulus G", indicating that the bulk phase of each composite material is more inclined to elastic solid, and the frequency oscillation test did not destroy the bulk phase structure.
[0107] The compressive strength of the amino acid hydrogel / amorphous calcium phosphate composite material prepared by the present invention at 85% strain is shown in Table 1, indicating that the amino acid hydrogel / amorphous calcium phosphate composite material prepared by the present invention has excellent mechanical properties.
[0108] Table 1 shows the compressive strength of the amino acid hydrogel / amorphous calcium phosphate composite material.
[0109]
[0110] To simulate an in vivo environment, the composite material was placed in simulated body fluid (SBF), with a volume ratio of amino acid hydrogel / amorphous calcium phosphate composite material to simulated body fluid of 1:40. It was then placed in an incubator at 37°C for 0-14 days. On days 3, 7, and 14, the amino acid hydrogel / amorphous calcium phosphate composite material was removed, washed, and freeze-dried. X-ray diffraction (XRD) was used to detect the crystal form of calcium phosphate in the composite material. Figure 2 As shown, on day 3, the crystallinity of calcium phosphate in each histidine hydrogel / amorphous calcium phosphate composite material was less than 40%, while on day 14, the crystallinity of calcium phosphate in each histidine hydrogel / amorphous calcium phosphate composite material was still less than 80%, indicating that the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention has good osteogenic activity.
[0111] After sterilization, each group of amino acid hydrogel / amorphous calcium phosphate composite materials were co-cultured with MC3T3-E1 cells for 7 days. The cell compatibility of each group of amino acid hydrogel / amorphous calcium phosphate composite materials was detected by live / dead staining. The amount of osteogenic-related genes in each group of cells was detected by RT-PCR. The expression of osteogenic-related genes included RUNX2, OPN, OSX and ALP, in order to detect the in vitro osteogenic capacity of each group of amino acid hydrogel / amorphous calcium phosphate composite materials. Figure 3 Fluorescence micrograph of MC3T3-E1 cells treated with acryloylglycine hydrogel / amorphous calcium phosphate composite material. Figure 4 Fluorescence microscopy image of MC3T3-E1 cells treated with acryloyl aspartate hydrogel / amorphous calcium phosphate composite material. Figure 5 Fluorescence micrograph of MC3T3-E1 cells treated with acryloylglutamate hydrogel / amorphous calcium phosphate composite material. Figure 3 , Figure 4 , Figure 5 In the middle, green fluorescence and red fluorescence represent live cells and dead cells, respectively. Figure 3 , Figure 4 , Figure 5 It can be seen that there is almost no red fluorescence in the fluorescence microscopy images of MC3T3-E1 cells treated with amino acid hydrogel / amorphous calcium phosphate composite materials, and the MC3T3-E1 cells show normal morphology, indicating that all groups of amino acid hydrogel / amorphous calcium phosphate composite materials have good biocompatibility.
[0112] To further verify the in vitro osteogenic capacity of the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention, a control group (CON) was set up, which used only MC3T3-E1 cells cultured in the specified medium; for example Figure 6 As shown, after 7 days of culture, the expression levels of RUNX2, OPN, OSX and ALP genes in MC3T3-E1 cells treated with amino acid hydrogel / amorphous calcium phosphate composite materials were significantly higher than those in the control group (CON), indicating that the amino acid hydrogel / amorphous calcium phosphate composite materials in each group have good in vitro osteogenic capacity.
[0113] A rat skull defect model was used to further verify the early in vivo osteogenic capacity of the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention. At 2 and 4 weeks after implantation of the amino acid hydrogel into the bone defect area, continuous fluorescent labeling with alizarin red / tetracycline was performed to assess new bone formation. Figure 7 As shown, the new bone formation rate after treatment with the amino acid hydrogel / amorphous calcium phosphate composite material prepared in this invention can reach 3-4 μm per day, which is significantly higher than the new bone formation rate after treatment with BNP@CS-GEL material in existing literature. Figure 8 )(Baicalin Nanocomplexes with an In Situ-Forming Biomimetic Gel Implant for Repair of Calvarial Bone Defects via Localized Sclerostin Inhibition.ACS Appl.Mater.Interfaces 2023,15,9044-9057).
Claims
1. A method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration, characterized in that, Includes the following steps: Step 1: Dissolve acryloyl amino acid monomer powder in double-distilled water to obtain a 1-3 mol / L acryloyl amino acid monomer solution; wherein the acryloyl amino acid monomer is acryloylglycine, acryloylaspartic acid, or acryloylglutamic acid. Step 2: Mix the acryloyl amino acid monomer solution obtained in Step 1 with the soluble calcium salt solution and stir for 2-30 minutes. Then, add the phosphate solution dropwise and continue stirring for 2-30 minutes to obtain mixed solution A. The volume ratio of the acryloyl amino acid monomer solution, the soluble calcium salt solution, and the phosphate solution is (20-50):(5-15):(2-9); the concentration of the soluble calcium salt solution is 10-30 mmol / L, and the concentration of the phosphate solution is 4-18 mmol / L. Step 3: Mix the mixed solution A obtained in Step 2 with the crosslinking agent to obtain mixed solution B; the crosslinking agent is polyethylene glycol diacrylate (PEGDA), and the average molecular weight of PEGDA is 250-10000; Step 4: Mix the mixed solution B obtained in Step 3 with the photoinitiator and stir for 2-30 min. Then, under blue light or ultraviolet light irradiation, initiate the polymerization reaction. The crosslinking reaction time is 5-30 s to obtain an amino acid hydrogel / amorphous calcium phosphate composite material.
2. The method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration according to claim 1, characterized in that, The preparation process of the acryloyl amino acid monomer powder in step 1 is as follows: Step 1.1: Mix amino acids with acryloyl chloride and react them. During the reaction, adjust the pH of the reaction solution to 7.5-8.
5. After the reaction is complete, adjust the pH of the reaction solution to 10.5-11.5 to obtain an alkaline solution. The molar ratio of the amino acids to acryloyl chloride is 1:(1.0-1.5). The amino acids are glycine, aspartic acid, or glutamic acid. Step 1.2: Wash the alkaline solution obtained in Step 1.1 with ethyl acetate to obtain a washed alkaline solution; The pH of the washed alkaline solution was adjusted to 1.5-2.5 to obtain an acidic solution; the volume ratio of the ethyl acetate to the alkaline solution was 1:(2-4). Step 1.3: Extract the acidic solution obtained in Step 1.2 with ethyl acetate, and then rotary evaporate to obtain a concentrated solution; the volume ratio of ethyl acetate to acidic solution is 1:(2-4); Step 1.4: The concentrate obtained in Step 1.3 is settled, centrifuged, and dried using n-hexane to obtain acryloyl amino acid monomer powder; the volume ratio of n-hexane to concentrate is 1:(5-8); the acryloyl amino acid monomer is acryloylglycine, acryloylaspartic acid, or acryloylglutamic acid.
3. The method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration according to claim 2, characterized in that: The reaction in step 1.1 is carried out at room temperature for 3-4 hours; the rotary evaporation temperature in step 1.3 is 20℃-30℃; the centrifugation speed in step 1.4 is 3000-10000 rpm, the centrifugation time is 2-5 minutes, the drying time is 3-8 hours, and the pressure is 0 ~ -0.1 MPa.
4. The method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration according to claim 1, characterized in that: In step 2, the soluble calcium salt is CaCl2, CaCl2·2H2O, Ca(NO3)2, or Ca(NO3)2·4H2O; the phosphate is Na2HPO4, K2HPO4, or (NH4)2HPO4.
5. The method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration according to claim 1, characterized in that: In step 3, the volume ratio of mixed solution A to crosslinking agent is (100-400):1; the stirring time is 2-30 min; and the mass concentration of crosslinking agent is 0.05%-0.2%.
6. The method for preparing an amino acid hydrogel / amorphous calcium phosphate composite material for bone defect regeneration according to claim 1, characterized in that: In step 4, the volume ratio of mixed solution B to photoinitiator is (15-40):1; the photoinitiator is 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone (2959), 2-hydroxy-2-methyl-1-phenyl-1-propanone (1173) or lithium phenyl (2,4,6-trimethylbenzoyl)phosphate (LAP), and the mass concentration of the photoinitiator is 2%-6%.
7. An amino acid hydrogel / amorphous calcium phosphate composite material, characterized in that: The composite material, an amino acid hydrogel / amorphous calcium phosphate composite for bone defect regeneration, as described in any one of claims 1-6, was prepared using the method described in claims 1-6.
8. The amino acid hydrogel / amorphous calcium phosphate composite material according to claim 7, characterized in that: The amino acid hydrogel / amorphous calcium phosphate composite material is an acryloylglycine / amorphous calcium phosphate composite material, an acryloylaspartic acid / amorphous calcium phosphate composite material, or an acryloylglutamic acid / amorphous calcium phosphate composite material.
Citation Information
Patent Citations
Mineralized Hydrogels and Methods of Making and Using Hydrogels
US20070098799A1
